Cel-Sci Corporation Common Stock (CVM)
0.3931
-0.0059 (-1.48%)
Cel-Sci Corporation is a biotechnology company focused on the development of innovative immunotherapy products for the treatment of cancer and other life-threatening diseases
The company is primarily engaged in the research and development of its lead product candidate, which leverages the unique properties of the immune system to combat tumors. With a commitment to enhancing patient outcomes, Cel-Sci explores novel therapeutic approaches and collaborates with research institutions to advance its clinical programs, aiming to bring new hope to patients in need of effective treatment options.
Previous Close | 0.3990 |
---|---|
Open | 0.3970 |
Bid | 0.3751 |
Ask | 0.3998 |
Day's Range | 0.3840 - 0.3999 |
52 Week Range | 0.3567 - 3.050 |
Volume | 321,264 |
Market Cap | 29.13M |
PE Ratio (TTM) | -0.7708 |
EPS (TTM) | -0.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 706,409 |
News & Press Releases
![](https://mms.businesswire.com/media/20250114061710/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
By CEL-SCI Corporation · Via Business Wire · January 14, 2025
![](https://mms.businesswire.com/media/20241231432429/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 16,130,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) was sold at an offering price of $0.31 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of approximately $5,000,000, before deducting placement agent fees and other offering expenses. All the shares and Pre-Funded Warrants in the offering were offered by the Company.
By CEL-SCI Corporation · Via Business Wire · December 31, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/30/Wall-Street-ai7-1.png?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024.
Via InvestorPlace · August 16, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/30/cancer.jpeg?width=1200&height=800&fit=crop)
Cel-Sci announces public offering of 16.13M shares at $0.31 per share, aiming to raise $5M for Multikine development and general purposes.
Via Benzinga · December 30, 2024
![](/next-assets/images/schema-image-default.png)
U.S. stock futures declined on Monday after ending lower on Friday. All four index futures slipped in trade.
Via Benzinga · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/30/Intel--Cleanspark--Super-Micro-Computer-.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/30/Things-To-Keep-In-Mind-While-Gifting-Sto.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 30, 2024
![](https://mms.businesswire.com/media/20241229624932/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 16,130,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.31 per share (inclusive of the Pre-Funded Warrant exercise price). Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $5,000,000. The offering is expected to close on December 31, 2024, subject to satisfaction of customary closing conditions.
By CEL-SCI Corporation · Via Business Wire · December 29, 2024
![](https://mms.businesswire.com/media/20241226952151/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants in lieu thereof) in a best efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
By CEL-SCI Corporation · Via Business Wire · December 27, 2024
![](https://mms.businesswire.com/media/20241212453035/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today highlights strong biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study.
By CEL-SCI Corporation · Via Business Wire · December 12, 2024
![](https://mms.businesswire.com/media/20241107683131/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to patient selection using low PD-L1 tumor expression in its confirmatory Registration Study for Multikine® (Leukocyte Interleukin, Injection)*. This study will focus on the treatment of newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement and low (TPS <10) PD-L1 tumor expression. This Registration Study, slated to commence in the first quarter of 2025, will enroll approximately 212 patients and prospectively confirm the favorable safety profile and the very favorable efficacy results demonstrated in the target population in CEL-SCI’s prior Phase 3 randomized study of 928 patients.
By CEL-SCI Corporation · Via Business Wire · November 7, 2024
![](https://mms.businesswire.com/media/20241021000924/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, Injection)* resulting from a recent U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, a public forum.
By CEL-SCI Corporation · Via Business Wire · October 22, 2024
![](https://mms.businesswire.com/media/20241001640049/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration (FDA) confirmatory Registration Study of Multikine® (Leukocyte Interleukin, Injection) in head and neck cancer.
By CEL-SCI Corporation · Via Business Wire · October 1, 2024
![](https://mms.businesswire.com/media/20240916023296/en/2243339/5/CEL-SCI_graph_09-16-24.jpg)
CEL-SCI Corporation (NYSE American: CVM) today reported new data from its concluded Phase 3 study of Multikine® (Leukocyte Interleukin, Injection)* that were presented at the European Society for Medical Oncology (ESMO) 2024 Congress on Saturday, September 14, 2024 in a poster titled “Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma for neoadjuvant Leukocyte Interleukin Injection immunotherapy”. This data is highly relevant to CEL-SCI’s 212 patient confirmatory Registration Study which has received the U.S. Food and Drug Administration’s (FDA) go-ahead and is currently under preparation.
By CEL-SCI Corporation · Via Business Wire · September 16, 2024
![](https://mms.businesswire.com/media/20240910816755/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today reported it will report new data from its Phase 3 study of Multikine (Leukocyte Interleukin, Injection)* at the European Society for Medical Oncology (ESMO) 2024 Congress which takes place from September 13 – 17, 2024 in Barcelona, Spain. A poster titled “Prognostic significance of diagnostic staging in treatment naïve, resectable locally advanced primary oral cavity squamous cell carcinoma for neoadjuvant Leukocyte Interleukin Injection immunotherapy” will be presented by the study’s co-author József Tímár MD, PhD, DSc, a prominent and highly respected pathologist.
By CEL-SCI Corporation · Via Business Wire · September 10, 2024
![](https://mms.businesswire.com/media/20240904760257/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (NYSE American: CVM) today reported it has received a decision letter from the United Kingdom’s Healthcare Products Regulatory Agency (MHRA) granting Multikine (Leukocyte Interleukin, Injection)* a product specific waiver for the treatment of head and neck cancer in a pediatric population of people up to 18 years of age. As a result, CEL-SCI will not be required to evaluate Multikine in a pediatric population as part of license and marketing clearance review in the UK.
By CEL-SCI Corporation · Via Business Wire · September 4, 2024
![](https://mms.businesswire.com/media/20240815767286/en/2216350/22/P3_Study_Population_chart.jpg)
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments.
By CEL-SCI Corporation · Via Business Wire · August 15, 2024
BioMedNewsBreaks — CEL-SCI Corp. (NYSE American: CVM) Closes on $10.8M Best-Efforts Offering
CEL-SCI (NYSE American: CVM), a cancer immunotherapy company, recently announced the closing of its previously announced best-efforts offering. The transaction involved the sale of 10,845,000 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per unit (inclusive of the pre-funded warrant exercise price). The offering raised $10,845,000 in gross proceeds before deductions. CEL-SCI intends to use the net proceeds to fund the continued development of Multikine (its lead investigational therapy), general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering.
Via Investor Brand Network · August 2, 2024
![](https://mms.businesswire.com/media/20240729532240/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced best-efforts offering of 10,845,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) was sold at an offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price), for gross proceeds of $10,845,000, before deducting placement agent fees and other offering expenses. All the shares and Pre-Funded Warrants in the offering were offered by the Company.
By CEL-SCI Corporation · Via Business Wire · July 29, 2024
![](https://mms.businesswire.com/media/20240726229829/en/226967/22/CEL-SCI_Logo.jpg)
CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the pricing of a best-efforts offering of 10,845,000 shares of its common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof). Each share of common stock (or Pre-Funded Warrant) is being sold at an offering price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). All of the shares and Pre-Funded Warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $10,845,000. The offering is expected to close on July 29, 2024, subject to satisfaction of customary closing conditions.
By CEL-SCI Corporation · Via Business Wire · July 26, 2024